|
Companies ink cancer MDx
agreement
February 2014
EDIT CONNECT
SHARING OPTIONS:
SAN FRANCISCO—CollabRx Inc. and Cynvenio Biosystems
Inc. have begun a multiyear agreement to utilize CollabRx technology and content resources to support the clinical interpretation of genetic sequencing-based
tests by Cynvenio. Per the terms of the agreement, several CollabRx products, including the Genetic Variant Annotation (GVA) Service, will be paired with
tumor mutation profiling performed by Cynvenio. Reports generated with the GVA Service will be offered with Cynvenio’s ClearID Breast Cancer blood
test, and Cynvenio will combine the test results with clinically actionable data provided by the GVA Service. Thomas Mika, chairman, president and CEO of
CollabRx, noted that, “We chose to extend CollabRx expertise and services to ‘liquid biopsy’ for the first time with Cynvenio because they
are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer.”
Code: Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|